CRISPR Therapeutics (CRSP) Tops Q4 EPS by 105c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of $1.10, $1.05 better than the analyst estimate of $0.05.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Independent Bank receives regulatory approval for HCB Financial acquisition
• Medtronic completes $550 million Scientia Vascular acquisition